Ranking results:

Past rankings:

2020
Criterium:	Position:
Overall Score:	> 1000
Total Number of Projects:	900-1000
2019
Criterium:	Position:
Overall Score:	500-600
Total Project Funding per Partner:	> 1000
Total Number of Projects:	400-500
2018
Criterium:	Position:
Overall Score:	> 1000
Total Project Funding per Partner:	> 1000
Total Number of Projects:	700-800
Networking Rank (Reputation):	> 1000
2016
Criterium:	Position:
Overall Score:	> 1000
Networking Rank (Reputation):	> 1000
2015
Criterium:	Position:
Overall Score:	> 1000
Networking Rank (Reputation):	> 1000
2014
Criterium:	Position:
Overall Score:	> 1000
Networking Rank (Reputation):	> 1000
2012
Criterium:	Position:
Overall Score:	700-800
Total Project Funding per Partner:	700-800
Total Number of Projects:	68
Total Project Funding:	700-800
Networking Rank (Reputation):	700-800
Networking Rank (Reputation):	700-800
Partner Constancy:	46
Project Leadership Index:	75
Diversity Index:	41

Ranking timeline:

Project Participation Performance(2012-01-01 - 2025-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 45
As coordinator: 1
As participant: 44
Sole participant: 0
Coordinator / Participant Ratio: 0.02^*

^*Ratio includes only projects with > 2 partners

Summary:

	Total project funding [€]:			Projects [No]:
Year:	coordinator^*	participant^*	per partner	as coordinator	as participant
2023	0	3.763.200	0		1
2022	0	7.856.504	0		1
2021	2.733.150	73.793.782	1.339.080	1	7
2020	0	32.597.381	0		4
2019	0	108.830.360	421.103		8
2018	0	130.275.644	0		4
2017	0	43.440.356	0		5
2016	0	64.482.031	0		7
2015	0	5.972.496	0		1
2014	0	5.998.346	124.247		1
2013	0	15.918.137	762.895		2
2012	0	17.316.160	201.181		3

^*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:	Projects [No]:
NOVARTIS PHARMA	22
JANSSEN PHARMACEUTICA NV	19
PFIZER LIMITED	18
SANOFIAVENTIS	13
ELI LILLY AND COMPANY LIMITED	12
UNIVERSITY COLLEGE LONDON	11
ASTRAZENECA	10
BAYER	10
UCB BIOPHARMA	10
CHARITE UNIVERSITAETSMEDIZIN BERLIN	8
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM	8
KATHOLIEKE UNIVERSITEIT LEUVEN	8
ABBVIE INC	7
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG	7
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT	7
KING'S COLLEGE LONDON	7
MERCK SHARP & DOHME CORP	7
STICHTING KATHOLIEKE UNIVERSITEIT	7
TAKEDA DEVELOPMENT CENTRE EUROPE	7
TAKEDA PHARMACEUTICALS INTERNATIONAL	7
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V	6
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE	6
KAROLINSKA INSTITUTE	6
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN	6
UNIVERSITEIT MAASTRICHT	6
UNIVERSITY OF NEWCASTLE UPON TYNE	6
UPPSALA UNIVERSITET	6
GOETEBORGS UNIVERSITET	5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	5
NOVO NORDISK	5
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT	5
STICHTING VUMC	5
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL	5
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	5
THE UNIVERSITY OF EDINBURGH	5
UNIVERSITAIR MEDISCH CENTRUM UTRECHT	5
UNIVERSITY OF CAMBRIDGE	5
ACADEMISCH ZIEKENHUIS GRONINGEN	4
ALZHEIMER EUROPE	4
BAYER AKTIENGESELLSCHAFT	4
COMMISSARIAT A L'ENERGIE ATOMIQUE	4
EUROPEAN CANCER PATIENT COALITION	4
FORUM DES PATIENTS EUROPEENS	4
H LUNDBECK AS	4
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS	4
INSTITUT PASTEUR	4
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN	4
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV	4
RIJKSUNIVERSITEIT GRONINGEN	4
SERVICIO MADRILENO DE SALUD	4
THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN HEREINAFTER TRINITY COLLEGE DUBLIN	4
UNIVERSITEIT GENT	4
ACADEMISCH ZIEKENHUIS LEIDEN	3
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN	3
ARTTIC	3
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS	3
ASTRAZENECA AB	3
EBERHARD KARLS UNIVERSITAET TUEBINGEN	3
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK	3
ELI LILLY AND COMPANY	3
EUROPEAN MOLECULAR BIOLOGY LABORATORY	3
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION	3
FUNDACIO SANT JOAN DE DEU	3
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE	3
INSTITUT DE RECHERCHES SERVIER	3
LUND UNIVERSITY	3
MEDIZINISCHE HOCHSCHULE HANNOVER	3
MEDIZINISCHE UNIVERSITAET WIEN	3
MEDIZINISCHE UNIVERSITAT INNSBRUCK	3
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE	3
ORION OYJ	3
OSPEDALE PEDIATRICO BAMBINO GESU	3
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON	3
REGION HOVEDSTADEN	3
STICHTING BURO ECNP	3
STICHTING LYGATURE	3
STICHTING VU	3
SYNAPTOLOGICS BV	3
TEAM IT RESEARCH SL	3
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	3
THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA	3
THE UNIVERSITY OF LIVERPOOL	3
TTOPSTART BV	3
UNIVERSITAET BERN	3
UNIVERSITAET ZUERICH	3
UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTUNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS	3
UNIVERSITAT WIEN	3
UNIVERSITATSKLINIKUM BONN	3
UNIVERSITE DU LUXEMBOURG	3
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK	3
UNIVERSITY COLLEGE DUBLIN	3
UNIVERSITY OF GLASGOW	3
AC IMMUNE	2
ACADEMIC MEDICAL CENTRE AMSTERDAM	2
AMGEN	2
AMGEN LIMITED	2
ARTTIC INNOVATION	2
BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM	2
BIOGEN IDEC LIMITED	2
BIOSCI CONSULTING BVBA	2

Constancy:

Total number of partners: 1098
Partner loyalty:
Frequent Partner: (> 2 projects): 477
Rare Partner: 621
Frequent / Rare Partner Ratio: 0.77

Project overview:

Start date	Project	acronym	role	funding	partners
2023-01-01	From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network	Maxima Butterfly	participant	3.763.200	36
2022-09-01	Risk and Resilience in Developmental Diversity and Mental Health	R2D2-MH	participant	7.856.504	26
2021-11-01	European platform for neurodegenerative disorders	EPND	participant	9.680.000	29
2021-10-01	Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies	SCREEN4CARE	participant	11.938.569	37
2021-10-01	Understanding the Biology of Human Enteroendocrine Cells	GutHormones	coordinator	2.733.150	2
2021-10-01	Optimal treatment for patients with solid tumours in Europe through Artificial intelligence	OPTIMA	participant	10.459.997	39
2021-07-01	Real World Handling of Protein Drugs - Exploration, Evaluation and Education	RealHOPE	participant	3.139.984	27
2021-02-01	Central Repository for Digital Pathology	BIGPICTURE	participant	32.319.825	51
2021-01-01	Drug Absorption in Geriatric Patients and Older People: a training network innovating drug development for the advanced age population	AGePOP	participant	2.790.443	6
2021-01-01	A fully integrated, animal-free, end-to-end modelling approach to oral drug product development	InPharma	participant	3.464.964	11
2020-11-01	Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment	Gravitate-Health	participant	9.280.000	42
2020-10-01	H2O Health Outcomes Observatory	H2O	participant	10.476.687	25
2020-09-01	Prioritisation and Risk Evaluation of Medicines in the EnviRonment	PREMIER	participant	4.550.000	25
2020-01-01	PharmaLedger	PharmaLedger	participant	8.290.694	30
2019-12-01	Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies	imSAVAR	participant	10.999.316	28
2019-11-01	Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases	IDEA-FAST	participant	20.997.523	47
2019-11-01	Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis	MIRIADE	participant	4.015.376	11
2019-11-01	Virtual IoT Maintenance System	VIMS	participant	2.345.830	4
2019-10-01	Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies	Immune-Image	participant	15.000.000	23
2019-09-01	Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions	3TR	participant	40.273.192	70
2019-03-01	Efficiently Networking European Neurodegeneration Research	NEURONET	participant	1.199.125	10
2019-02-01	Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease	TransBioLine	participant	13.999.998	29
2018-10-01	European Training Network to Diagnose, Understand and Treat Stargardt Disease, a Frequent Inherited Blinding Disorder	StarT	participant	3.776.714	15
2018-06-01	Autism Innovative Medicine Studies – 2 – Trials	AIMS-2-TRIALS	participant	54.999.999	48
2018-05-01	conect4children (COllaborative Network for European Clinical Trials For Children)	c4c	participant	67.000.000	47
2018-03-01	Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes.	PARADIGM	participant	4.498.931	35
2017-10-01	European Quality In Preclinical Data	EQIPD	participant	4.495.523	30
2017-09-01	Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management	eTRANSAFE	participant	20.000.000	27
2017-09-01	Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076	MACUSTAR	participant	8.025.000	13
2017-02-01	Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055	DO-IT	participant	3.549.833	36
2017-01-01	ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064	ITCC-P4	participant	7.370.000	21
2016-11-01	Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020	ROADMAP	participant	3.998.250	26
2016-11-01	Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976	PHAGO	participant	8.838.000	20
2016-10-01	Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966	PREFER	participant	6.000.000	33
2016-04-01	Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916	PRISM	participant	8.080.000	23
2016-03-01	FRAGments training NETwork	FRAGNET	participant	3.842.482	13
2016-01-01	An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century	EU-ToxRisk	participant	27.798.299	41
2016-01-01	Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders	COSYN	participant	5.925.000	14
2015-05-01	Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways	EYE-RISK	participant	5.972.496	12
2014-02-01	Translating neuroimaging findings from research into clinical practice	PSYSCAN	participant	5.998.346	15
2013-10-01	Deciphering inter- and intracellular signalling in schizophrenia	IN-SENS	participant	3.918.138	13
2013-10-01	Hepatic and Cardiac Toxicity Systems modelling	HECATOS	participant	11.999.999	14
2012-05-01	New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier	TRANS-INT	participant	8.000.000	17
2012-02-01	Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer	RESPONSIFY	participant	5.990.195	12
2012-02-01	Scalable, Standard based Interoperability Framework for Sustainable Pro-active Post Market Safety Studies	SALUS	participant	3.325.965	10

F. HOFFMANN-LA ROCHE AG - Switzerland